Stuart Therapeutics has initiated a phase 3 clinical trial for its ST-100 ophthalmic solution for dry eye disease. The drug candidate is based on the company’s PolyCol technology and has the potential to provide a fast and effective treatment for a broad range of dry eye disease patients. The trial will involve 320 participants and will assess the safety and efficacy of the ST-100 solution compared to a placebo. The company’s research has also suggested the potential for a fast-acting, highly differentiated treatment that can improve tear production, relieve symptoms, reduce ocular surface damage, and improve visual acuity.
Source link
Stuart Therapeutics announces first patient visit in ST-100 trial for dry eye
